With additional testing for nonobstructive coronary artery disease (CAD), researchers effectively diagnosed microvascular and/or vasospastic angina—as well as non-cardiac related chest pain—and used that information to guide therapy decisions and significantly improve angina and quality-of-life outcomes.

INSIGHTEC®,a global medical technology innovator of incisionless surgery, today announced that the U.S. Food and Drug Administration (FDA) has approved Exablate Neuro™ compatibility for the state-of-the-art MRI Scanners Magnetom Skyra, Prisma and Prisma[fit] from Siemens Healthineers to treat patients with essential tremor (ET).

Radiology staff at VCU Medical Center, the comprehensive care center of VCU Health located in downtown Richmond, Virginia, perform approximately 160,000 imaging procedures a year with six CARESTREAM DRX-Evolution Systems, nine CARESTREAM DRX-Revolution Mobile X-ray Systems, and three room-based imaging systems that have been converted to DR with CARESTREAM DRX-1 in-room retrofits and the company’s DRX detectors.

Fractional flow reserve (FFR) measured using coronary angiogram achieved greater diagnostic accuracy compared to invasive pressure-wire, according to a 10-center study published in Circulation.

Intelerad Medical Systems™, a leader in enterprise workflow solutions, is pleased to announce that following the retirement of Randall Oka, its board of directors has appointed Paul Lepage as its new president and chief executive officer.

Results from the BIONYX Trial found the Resolute Onyx stent provided better x-ray visibility compared to Orsiro, an established cobalt-chromium strut stent, according to findings presented Monday, Sept. 24, at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in San Diego.

Researchers—led by Rahul Deo, MD, PhD, of the division of cardiovascular medicine at Brigham and Women’s Hospital in Boston—have developed the first pipeline for automated echocardiogram interpretation, according to an article published Sept. 21 by Cardiovascular Business (CVB).

Compared to heart failure patients with severe secondary mitral regurgitation who were treated with guideline-directed medical therapy alone, those randomized to a MitraClip procedure plus optimal medical therapy demonstrated relative reductions of 47 percent for heart failure hospitalizations and 38 percent for mortality at two years of follow-up.